Hostname: page-component-669899f699-ggqkh Total loading time: 0 Render date: 2025-04-24T23:28:09.897Z Has data issue: false hasContentIssue false
  • English
  • Français

Intravenous prostaglandin E1 (alprostadil) bolus in ductus arteriosus-dependent CHD: valid or absolutely contraindicated?

Published online by Cambridge University Press:  05 July 2023

Jose L. Colín Ortiz Open the ORCID record for Jose L. Colín Ortiz [Opens in a new window] ,
Angel Cruz Hernández Open the ORCID record for Angel Cruz Hernández [Opens in a new window] ,
Jorge A. Silva Estrada Open the ORCID record for Jorge A. Silva Estrada [Opens in a new window] ,
Roberto Maldonado Alonso ,
Carlos A. Corona Villalobos ,
Carlos González Rebeles Guerrero  and
Linda F. Pérez Pérez
Jose L. Colín Ortiz*
Affiliation:
Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico
Angel Cruz Hernández
Affiliation:
Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico
Jorge A. Silva Estrada
Affiliation:
Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico
Roberto Maldonado Alonso
Affiliation:
Department of Pediatric Cardiology, Hospital of the Poblano Child, Puebla, Mexico
Carlos A. Corona Villalobos
Affiliation:
Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico
Carlos González Rebeles Guerrero
Affiliation:
Department of Paediatric Cardiology, National Institute of Paediatrics, Coyoacan, Mexico City, Mexico
Linda F. Pérez Pérez
Affiliation:
Department of Pediatric Cardiology, Hospital of the Poblano Child, Puebla, Mexico
*
Corresponding author: J. L. Colín Ortiz; Email: colin_jldgo@yahoo.com.mx
Get access Rights & Permissions [Opens in a new window]

Abstract

The use of prostaglandin E1 is well documented in ductus arteriosus-dependent CHD or in neonatal pulmonary pathologies that cause severe pulmonary hypertension. The intravenous infusion is well established in loading infusion and maintenance with an onset of action of 30 minutes until 2 hours or even more. Our aim is to report three patients with pulmonary atresia that presented hypercyanotic spell due to a ductal spasm during cardiac catheterisation in whom the administration of a bolus of alprostadil reversed the spasm and increased pulmonary flow, immediately stabilising the condition of the patients allowing subsequent successful stent placement with no serious complications or sequelae after the administration of the bolus. More studies are needed to make a recommendation regarding the use of alprostadil in bolus in cases where the ductal spasm might jeopardise the life of the patient.

Keywords

Prostaglandin E1alprostadilductal spasmhypercyanotic spell
Type
Original Article
Information
Cardiology in the Young , Volume 34 , Issue 2 , February 2024 , pp. 314 - 318
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Von Euler, OS. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesinglandin). J Physiol 1936; 88: 213–234.CrossRefGoogle Scholar
Bergström, S, Carson, LA, Weeks, JR. The prostaglandins. A family of biologically-active lipids. Pharmacol Rev 1948; 20: 1–48.Google Scholar
Bergström, S, Sjovall, J. The isolation of prostaglandins. Acta Chem Scand 1957; 11: 1080–1087.CrossRefGoogle Scholar
Freed, MD, Heyman, MA, Lewis, AB, et al. Prostaglandins E1 infants with Ductus Arteriosus de-pendent congenital heart disease. Circulation 1981; 64: 899–905.CrossRefGoogle Scholar
Lewis, AB, Freed, MD, Heynman, MA, et al. Side effects of theraphy with prostaglandin E1 in infants with critical congenital heart disease. Circulation 1981; 64: 893–898.CrossRefGoogle Scholar
Palomares, CR, Vera, TO. Prostaglandinas. Fichero farmacológico, McGraw Hill, EUA, 2013.Google Scholar
Dice, JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006; 11: 233–236.Google ScholarPubMed